In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
|Podcasts|May 21, 2021
OncView Podcast: Optimizing Treatment With Extended Adjuvant Therapy for HR+ Breast Cancer
Author(s)Kristie L. Kahl
In this special edition of the “Oncology Peer Review On-The-Go” podcast, CancerNetwork spoke with Reshma L. Mahtani, DO, about genomic testing to optimize treatment outcomes in HR-positive breast cancer.
Advertisement
As part of its OncView video series, CancerNetwork spoke with Reshma L. Mahtani, DO, Sylvester Comprehensive Cancer Center, about the current role of genomic testing in HR-positive breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting.
In the video series, Mahtani discussed the following:
Extended Adjuvant Therapy for HR+ Breast Cancer NCCN Updates to Genomic Testing in HR+ Breast Cancer Genomic Testing for HR+ Breast Cancer: Best Practices Utilization of The Breast Cancer Index for HR+ Breast Cancer Optimizing Treatment Outcomes in HR+ Breast Cancer
To watch more videos in CancerNetwork’s OncView series, visit
Advertisement
Related to this article
10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.
Daniel C. McFarland, DO, and Yesne Alici, MD, discussed medical aid in dying in cancer care, New York’s safeguards, and the role of psycho-oncology.
In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.
William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.
Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
William A. Hall, MD, explains how fewer visits, no concurrent chemotherapy, and adaptive MRI guidance may have preserved quality of life with SBRT.
“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Where Does Intensity-Modulated Proton Therapy Fit in Prostate Cancer?
2
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
3
FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC
4
IMS 2026: Key Updates Across The Multiple Myeloma Paradigm
5